Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q

SIMPLE SUMMARY: Lenalidomide is an immunomodulatory drug (IMiD) that has achieved clinical efficacies in multiple myeloma (MM) and myelodysplastic syndromes (MDS) with a single deletion of chromosome 5q (del(5q)). However, many patients treated with lenalidomide relapse and become resistant. Recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Isaac, Phan, Tra Mi, Fang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534127/
https://www.ncbi.nlm.nih.gov/pubmed/34680233
http://dx.doi.org/10.3390/cancers13205084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534127/
https://www.ncbi.nlm.nih.gov/pubmed/34680233
http://dx.doi.org/10.3390/cancers13205084

Ejemplares similares